- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03393013
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis (MISSION)
A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis (MISSION)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a Phase 1b/2, open-label, multi-center study in which patients received zetomipzomib administered as a SC injection weekly for either 13 weeks (Phase 1b) or for 24 weeks (Phase 2). In both phases, safety assessments continued for up to 12 weeks following the last dose of zetomipzomib.
Phase 1b was an open-label, multiple dose escalation study designed to evaluate the safety and tolerability of escalating doses of zetomipzomib when administered in addition to standard-of-care therapy in patients with SLE with or without nephritis. For each cohort, at least 6 patients were to be enrolled to assure the availability of at least 4 evaluable patients. Decisions to escalate, expand, or decrease the dose level or dosing frequency following the first 4 weeks of dosing for at least 4 evaluable patients in a cohort were made following review by a data monitoring committee (DMC).
The zetomipzomib formulations and doses administered by cohort in Phase 1b were:
- Cohort 1: zetomipzomib frozen maleate, 45 mg weekly × 13 weeks
- Cohort 2: zetomipzomib frozen maleate, 60 mg weekly × 13 weeks
- Cohort 2a: zetomipzomib frozen maleate, 30 mg weekly × 2 weeks, followed by 45 mg weekly × 2 weeks, followed by 60 mg weekly × 9 weeks
- Cohort 2b: zetomipzomib lyophile, 30 mg weekly × 1 week, followed by 60 mg weekly × 12 weeks
- Cohort 2c: zetomipzomib lyophile, 30 mg weekly × 1 week, followed by 60 mg weekly × 12 weeks (tolerability strategies cohort)
- Cohort 3: zetomipzomib lyophile, 30 mg weekly × 1 week, followed by 75 mg weekly × 12 weeks
The Phase 2 portion of the open-label study was designed to evaluate the renal response, safety, and tolerability of a single dose level (60 mg) of zetomipzomib administered weekly in addition to standard therapy in patients with active proliferative lupus nephritis (LN) (Class III or IV, with or without Class V disease) with a UPCR ≥1.0. Patients must have been on standard therapy for LN including at least 1 immunosuppressive agent. Zetomipzomib was administered as a SC injection weekly for 24 weeks (including a step up from an initial Week 1 dose of 30 mg).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Health
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
-
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia, 080020
- Clinica de la Costa
-
Barranquilla, Atlantico, Colombia, 080020
- Centro Integral de Reumatologia de Caribe CIRCARIBE S.A.S
-
-
Bucaramanga
-
Santander, Bucaramanga, Colombia, 680003
- Medicity SAS
-
-
Santander
-
Bucaramanga, Santander, Colombia, 680003
- Servimed S.A.S.
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Colombia, 076001
- Clinica de Artritis Temprana
-
-
-
-
-
Mexico City, Mexico, 14080
- Instituto Nacional de Cardiologia Ignacio Chavez
-
Mexico City, Mexico, 14080
- Instituto Nacional de Ciencias Médicas y Nutricion "Salvador Zubiran"
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44160
- Centro Integral de Reumatologia SA de CV
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64020
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
-
-
-
-
Lima, Peru, 15023
- Investigaciones Clinicas SAC
-
Lima, Peru, 15431
- Unidad de Investigacion en Reumatologia e Inmunologia Clinica San Juan Bautista
-
-
La Libertad
-
Trujillo, La Libertad, Peru, 13011
- Centro de Investigación Clínica Trujillo E.I.R.L/ Clínica Peruano Americana S.A.
-
-
-
-
-
Łódź, Poland, 90-368
- Bioclinica
-
-
-
-
-
Kemerovo, Russian Federation, 650070
- Medical Center Revma-Med
-
Kemerovo, Russian Federation, 650066
- Kuzbass Clinical Hospital
-
Togliatti, Russian Federation, 445009
- Tolyatti City Clinical Hospital #1
-
-
-
-
Kyiv Governorate
-
Kyiv, Kyiv Governorate, Ukraine, 01135
- Harmoniya Krasy
-
-
-
-
California
-
Los Angeles, California, United States, 990022
- Academic Medical Research Institute
-
Upland, California, United States, 91786
- Inland Rheumatology Clinical Trials, Inc.
-
-
Florida
-
Miami, Florida, United States, 33165
- Hope Clinical Trials, Inc.
-
Miami, Florida, United States, 33136
- SouthCoast Research Center, Inc.
-
Orlando, Florida, United States, 32808
- Omega Research Maitland
-
Palm Harbor, Florida, United States, 34684
- Arthritis Center, Inc
-
Tampa, Florida, United States, 33614
- Advent Health Medical Group
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
New York
-
Great Neck, New York, United States, 11021
- Northwell Health
-
New York, New York, United States, 10016
- NYU Langone Orthopedic Center - Seligman Center for Advanced Therapeutics
-
Rochester, New York, United States, 14620
- University of Rochester Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- SC Nephrology & Hypertension Center, Inc.
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Ramesh C. Gupta, MD
-
-
Texas
-
El Paso, Texas, United States, 79902
- MedResearch, Inc.
-
Houston, Texas, United States, 77084
- Accurate Clinical Management, LLC
-
Houston, Texas, United States, 77034
- Accurate Clinical Research, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Phase 1b:
- Fulfilled the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification for SLE
- Had a positive antinuclear antibody (ANA) titer, anti-double stranded DNA (dsDNA) antibody titer, or a positive anti-Smith antibody titer
- Had active SLE (as indicated by Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K] score ≥4), and
- Had received at least 1 prior therapy for SLE
Phase 2:
- Had active proliferative LN (Class III or IV, with or without Class V disease)
- Had a UPCR ≥1.0 measured in 24-hour urine collection
- Had a histologic diagnosis of LN on renal biopsy within the prior 2 years; for biopsies > 1 year before the Screening visit, one of the following must also be present at screening: low C3, low C4, or anti-ds-DNA elevated to above normal range
- Fulfilled the 2012 SLICC classification for SLE
- Had a positive ANA titer, anti-dsDNA antibody titer, or anti-Smith antibody titer, and
- Were currently receiving ≥1 immunosuppressive agent at a stable dose and route of administration for ≥8 weeks. If the patient is also on corticosteroids then must be on a stable dose for ≥ 2 weeks prior to Baseline
Key Exclusion Criteria:
Phase 1b:
Current or medical history of:
- Central nervous system manifestations by autoimmune disease
- Overlapping autoimmune condition that may affect study assessments/outcomes
- Antiphospholipid syndrome with history of thromboembolic event of within the 52 weeks prior to Screening
- Malignancy of any type, with exceptions for in situ cancer that has been completely excised and certain cancers >5 years ago
- Positive test at Screening for HIV, hepatitis B/C
- Major surgery within 4 weeks before signing informed consent form or planned major surgery during the study period
Phase 2:
Current or medical history of:
- Central nervous system manifestations of SLE
- Overlapping autoimmune condition that may affect study assessments/outcomes
- Antiphospholipid syndrome with history of thromboembolic event of within the 52 weeks prior to Screening
- Malignancy of any type within the last 5 years, with exceptions for appropriately excised and cured cervical carcinoma in situ or excised basal or squamous cell carcinomas of the skin
- Has received dialysis within the 52 weeks prior to Screening
- Positive test at Screening for HIV, hepatitis B/C
- Major surgery within 12 weeks before signing informed consent form or planned major surgery during the study period
- Use of investigational therapy or device, and/or participation in an investigational trial <8 weeks or 5 half-lives, whichever is longer, prior to Baseline; Patients who participated in Phase 1b of KZR-616-002 are excluded from Phase 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KZR-616 45 mg + standard of care therapy (Phase 1b)
Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. Two Phase 1b cohorts received 45 mg at some point during the study. Cohort 1 received 45 mg zetomipzomib frozen maleate weekly for 13 weeks. Cohort 2a followed a step-up dosing procedure. Patients received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks. KZR-616 was administered as a SC injection. |
Subcutaneous Injection of KZR-616
Other Names:
|
Experimental: KZR-616 60 mg + standard of care therapy (Phase 1b)
Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. Four Phase 1b cohorts received 60 mg at some point during the study. Cohort 2 received 60 mg zetomipzomib frozen maleate weekly for 13 weeks. Cohorts 2a, 2b, and 2c all followed a step-up dosing procedure. Patients in Cohort 2a received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks. Patients in Cohort 2b received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks. Patients in Cohort 2c (tolerability strategies cohort) received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks. KZR-616 was administered as a SC injection. |
Subcutaneous Injection of KZR-616
Other Names:
|
Experimental: KZR-616 75 mg + standard of care therapy (Phase 1b)
Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. One Phase 1b cohort received 75 mg at some point during the study. Cohort 3 followed a step-up dosing procedure. Patients in Cohort 3 received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 75 mg weekly for 12 weeks. KZR-616 was administered as a SC injection. |
Subcutaneous Injection of KZR-616
Other Names:
|
Experimental: KZR-616 60 mg + standard therapy (Phase 2)
60 mg dose level of KZR-616 selected based on data from the phase 1b dose escalation and administered to patients with active lupus nephritis in combination with standard therapy including at least one immunosuppressive agent. KZR-616 was administered as a SC injection weekly at a dose of 60 mg for 24 weeks (including a step-up from an initial Week 1 dose of 30 mg). ** See Limitations/Caveats for additional information |
Subcutaneous Injection of KZR-616
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Number of Patients Who Experienced at Least One Treatment-Related Treatment-Emergent Adverse Event
Time Frame: 25 weeks
|
The safety and tolerability of zetomipzomib (KZR-616) when administered as a subcutaneous injection weekly for 13 weeks in adult patients with systemic lupus erythematous (SLE) with and without nephritis, as assessed by number of patients who experienced at least one treatment-related treatment-emergent adverse event. For additional information about the safety and tolerability of KZR-616, please reference the adverse events section of this posting. |
25 weeks
|
Phase 2: Number of Patients With Lupus Nephritis With a 50% Reduction in UPCR
Time Frame: 24 weeks
|
To assess the number of patients with lupus nephritis with a 50% reduction in UPCR after 24 weeks of weekly SC injections with KZR-616 when compared to baseline.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: PK of KZR-616 (Cmax)
Time Frame: 8 hours
|
This is the maximum observed plasma concentration (Cmax) observed after administration of KZR-616 at Week 5.
The PK parameters were calculated using all timepoints at which the concentration was measured, ie.
predose and 5, 15, 30 minutes, 1, 2, 4, and 8 hours postdose.
|
8 hours
|
Phase 1b: PK of KZR-616 (Tmax)
Time Frame: 8 hours
|
This is the time to maximum observed plasma concentration (tmax) observed after administration of KZR-616 at Week 5.
The PK parameters were calculated using all timepoints at which the concentration was measured, ie.
predose and 5, 15, 30 minutes, 1, 2, 4, and 8 hours postdose.
|
8 hours
|
Phase 1b: PK of KZR-616 (AUC)
Time Frame: 8 hours
|
This is the area under the curve (AUC) from predose through 8 hour postdose observed after administration of KZR-616 at Week 5.
The PK parameters were calculated using all timepoints at which the concentration was measured, ie.
predose and 5, 15, 30 minutes, 1, 2, 4, and 8 hours postdose.
|
8 hours
|
Phase 2: Number of Patients With a Partial Renal Response
Time Frame: 24 weeks
|
Number of patients with a partial renal response (PRR) after 24 weeks of treatment, as defined by:
Count of patients below includes those who satisfy all three of the above criteria. |
24 weeks
|
Phase 2: Safety and Tolerability of KZR-616 When Administered as a SC Injection Weekly for 24 Weeks
Time Frame: 37 weeks
|
Exposure adjusted adverse event incidence rate for Injection Site Reactions and Systemic Injection Reactions. For additional information about the safety and tolerability of KZR-616, please reference the adverse events section of this posting. |
37 weeks
|
Phase 1b: Recommended Phase 2 Doses of Zetomipzomib When Administered as a Subcutaneous Injection
Time Frame: 25 weeks
|
The safety data from Phase 1b were used to determine a recommended dose of zetomipzomib to administer to patients with active proliferative lupus nephritis in Phase 2 of this study.
As pre-specified in the study protocol, this outcome measure was to be determined qualitatively through discussion of relevant information from the Phase 1b portion of the trial at a data monitoring committee meeting.
|
25 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kezar, Kezar Life Sciences, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Kidney Diseases
- Urologic Diseases
- Connective Tissue Diseases
- Glomerulonephritis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Lupus Erythematosus, Systemic
- Nephritis
- Lupus Nephritis
Other Study ID Numbers
- KZR-616-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on KZR-616
-
Kezar Life Sciences, Inc.CompletedDermatomyositis | PolymyositisUnited States
-
Kezar Life Sciences, Inc.WithdrawnImmune Thrombocytopenia | Autoimmune Hemolytic AnemiaPoland, United States, Australia, Italy, Russian Federation
-
Kezar Life Sciences, Inc.CompletedDermatomyositis | PolymyositisUnited States, Czechia, Germany
-
Kezar Life Sciences, Inc.RecruitingLupus NephritisUnited States, Korea, Republic of, Australia, Malaysia, Taiwan, South Africa, Singapore, United Kingdom, Puerto Rico, Croatia, India, Greece, Spain, Brazil, Philippines, Guatemala, Argentina, Portugal
-
Kezar Life Sciences, Inc.RecruitingAutoimmune HepatitisUnited States
-
Kezar Life Sciences, Inc.Recruiting
-
Biosuccess Biotech Co., Ltd.TerminatedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
University of EdinburghNHS Lothian; Chief Scientist Office of the Scottish GovernmentCompletedOverdoseUnited Kingdom